Ro partnered with Eli Lilly in December 2024 to offer Zepbound vials through LillyDirect integration, and with Novo Nordisk in 2025 to offer Wegovy at reduced prices. The company launched a free GLP-1 Supply Tracker in May 2024 to crowdsource medication availability information. In January 2026, Ro partnered with Novo Nordisk to offer the first FDA-approved GLP-1 pill. Celebrity partnerships with Charles Barkley and Serena Williams in 2025 aimed to destigmatize GLP-1 treatment for weight management.
All receipts on Ro
Ro
Ro laid off 18% of staff (around 135 employees from 750 total) in June 2022 despite having raised $150M just months earlier at a $7B valuation. CEO Zachariah Reitano told employees cuts were to "manage expenses" and "better map our resources to our current strategy." Laid-off workers received two months severance plus healthcare, but received no transition period citing "patient privacy obligations." The layoffs impacted most of the recruiting team.
Share this receipt
Posts with the receipt card attached.
Post this receiptDownload card
Ro — Layoffs: OPPOSED Ro laid off 18% of staff (around 135 employees from 750 total) in June 2022 despite having raised $150M just months earlier at a $7B valuation. CEO Zachariah Reitano told employ… https://reciepts.tech/stance/1426
More on Ro
See all →When Ro laid off 18% of staff in June 2022, CEO Zachariah Reitano stated the company took "full responsibility." Affected workers received two months severance plus healthcare, and Ro extended the options exercise window to three years. The company offered career services to affected staff. However, workers received no transition period, with Ro citing "patient privacy obligations" for immediate terminations. Glassdoor reviews indicate company morale never fully recovered after the reduction in force.